Allele | pip-squeak | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mutation Type | critical splice acceptor site (2 bp from exon) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chromosome | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coordinate | 70,505,956 bp (GRCm39) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Base Change | T ⇒ A (forward strand) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene | Chrne | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Name | cholinergic receptor, nicotinic, epsilon polypeptide | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synonym(s) | AChrepsilon, Acre | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chromosomal Location | 70,505,709-70,510,042 bp (-) (GRCm39) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MGI Phenotype |
FUNCTION: This gene encodes the epsilon subunit of the muscle-derived nicotinic acetylcholine receptor, a pentameric neurotransmitter receptor and member of the ligand-gated ion channel superfamily. The acetylcholine receptor changes subunit composition shortly after birth when the epsilon subunit replaces the gamma subunit seen in embryonic receptors. In mice, deficiency of this gene can lead to a decline in the number of nicotinic acetylcholine receptors at neuromuscular junctions and causes progressive muscle weakness, atrophy and premature death. Mutations in this gene serve as a pathophysiological model for human congenital myasthenia. Several alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Nov 2012] PHENOTYPE: Homozygotes for targeted null mutations exhibit reduced AChR receptor density at neuromuscular synapses, impaired neuromuscular transmission, progressive muscular weakness and atrophy, and lethality at 2-3 months of age. [provided by MGI curators] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accession Number | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mapped | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amino Acid Change | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institutional Source | Beutler Lab | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Model | predicted gene model for protein(s): [ENSMUSP00000014753 †] [ENSMUSP00000099616 †] † probably from a misspliced transcript | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AlphaFold | P20782 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SMART Domains |
Protein: ENSMUSP00000014753 Gene: ENSMUSG00000014609
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predicted Effect | probably null | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SMART Domains |
Protein: ENSMUSP00000099616 Gene: ENSMUSG00000014609
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predicted Effect | probably null | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Meta Mutation Damage Score | 0.9495 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is this an essential gene? | Probably nonessential (E-score: 0.080) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phenotypic Category | Autosomal Recessive | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Candidate Explorer Status | loading ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Single pedigree Linkage Analysis Data |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Penetrance | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alleles Listed at MGI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lab Alleles |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mode of Inheritance | Autosomal Recessive | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Local Stock | Live Mice | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repository | MMRRC:37601 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Last Updated | 2016-05-13 3:09 PM by Anne Murray | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Record Created | 2014-09-20 11:58 AM by Jeff SoRelle | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Record Posted | 2015-01-13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phenotypic Description |
The pip-squeak phenotype was identified among G3 mice of the pedigree R1378, some of which showed reduced body weights (Figure 1). Some mice also exhibited premature lethality by postnatal day (P) 70-80. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nature of Mutation |
Whole exome HiSeq sequencing of the G1 grandsire identified 50 mutations. The body weight phenotype was linked to a mutation in Chrne: an A to T transversion at base pair 70,615,130 (v38) on chromosome 11, or base pair 4,501 in the GenBank genomic region NC_000077. Linkage was found with a recessive model of inheritance (P = 3.655 x 10-16), wherein 3 variant homozygotes departed phenotypically from 9 homozygous reference mice and 14 heterozygous mice (Figure 2). The mutation is located with intron 11, two nucleotides from the next exon (exon 12). The Chrne transcript contains 12 total exons. Currently, it is unknown how the pip-squeak mutation affects splicing of the gene. The placement of putative cryptic acceptor sites within exon 12 are unknown.
The mutated nucleotide is indicated in red lettering; the acceptor splice site of intron 11 is indicated in blue lettering. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illustration of Mutations in Gene & Protein |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protein Prediction |
Chrne encodes the epsilon (ɛ) subunit of the adult-type nicotinic acetylcholine receptor (AChR). Each subunit is similar in size and exhibits the same three-dimensional fold (1) (see the Background section for more details on the AChR channel. Amino acids 1-20 constitute a signal peptide that is removed upon translocation into the endoplasmic reticulum [Figure 3; (2;3)]. The N-terminus of each of the subunits (amino acids 21-239 in the ɛ subunit) is extracellular and consists of a β-sandwich core with ten β-strands and one α-helix (1). The region near Ser126 and Tyr135 within the extracellular N-terminus is important for AChR assembly in the mouse (3). Ser126 and Tyr135 increased surface AChR expression by promoting the formation of a heterodimer between the ɛ and α subunits of the AChR (3). The rat ɛ subunit has amino acid differences at amino acid 126 and 135 compared to the mouse sequence. As a result, the rat ɛ subunit is approximately 10 times less effective than that of the mouse in supporting surface expression of AChRs when expressed in COS cells (3). The transmitter-binding sites of AChR are within the extracellular domain at the α-ε and α-δ interfaces (4;5). The sites form a gate region in the transmembrane domain that regulates ionic conductance (6). Within the transmitter-binding sites are the conserved prolines ProD1 (Pro140 in the ɛ subunit) and ProD2 (Pro141 in the ɛ subunit). Mutation of the ε-ProD2 proline residue to a leucine (ϵProD2-L) has been linked to congenital myasthenic syndrome (CMS) (4). The mutation reduces the resting affinity of the α-ε transmitter-binding site and the gating equilibrium constant (4). Each of the AChR subunits has four transmembrane domains designated as M1-M4 (amino acids 240-264 (M1), 273-291 (M2), 307-328 (M3), and 457-480 (M4) in the ɛ subunit) (1;7). The M1 domains of the AChR function in agonist dissociation and channel gating (8). Five amino acids join the β10 strand from the ECD with the M1 helix and is termed the “pre-M1” linker (9). Each of the linkers in the AChR subunits contains a conserved central positively charged Arg (Arg3’) that is flanked by positively charged amino acids. The role of is Arg3’ unclear. Some studies proposed that disruption of a salt bridge between Arg3’ and loop 2 residue αGlu45 occurs during gating of the channel (12). Another study propose that the role of Arg3’ in gating is not significant, but that it is essential for receptor expression (10). A third study found that mutation of Arg3’ in any of the subunits result in reduced channel expression and alters the gating equilibrium constant (9). The opening and closing of the gate near the M2 equator involves the rearrangement of atoms in all five subunits (9). The M2 domains shape the lumen of the pore and forms the gate of the closed channel (11). The M3 domains also contribute to channel gating (12;13). The M4 domains shift during channel activation and may function in regulating AChR kinetics by interacting with membrane lipids (14;15). The M1, M3, and M4 helices are stabilized in the membrane by clustering of hydrophobic side chains around a central aromatic residue (1;7). Two Chrne splice variants have been identified. An mouse-specific ε subunit splice variant, εs, lacks exon 5 and encodes a truncated protein that lacks a portion of the N-terminal domain that contains an linked glycosylation site (Asn 161) and the two cysteines needed for the formation of a disulfide-bonded intermolecular loop [Cys148 and Cys162; (16)]. An ε subunit splice variant, εt, lacks exon 8 and encodes a truncated protein that contains the extracellular N-terminus, the M1 transmembrane domain, and a portion of the first intracellular loop (17). Ghedini et al. propose that if the splice variant is translated, it may be a non-functional isoform due to the loss of the M2 domain that forms the ionic channel (17). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expression/Localization | Chrne transcription is regulated by cell type and occurs only in the synaptic nuclei of fully differentiated skeletal muscle cells at or around the time of birth (18-21). Chrne is expressed at low levels in neonatal mouse and rat myotubules (22). After birth, the level of Chrne increased 10-fold (23;24) and is confined to the developing motor endplate (19). Chrne levels are maintained in the adult (19;20). In primary mouse muscle cultures, the glycoprotein ARIA (AChR-inducing activity) was able to increase the synthesis of AChR and increase Chrne mRNA levels 10-fold in mouse myotubules (22). Martinou et al. propose that ARIA induces the adult-type AChRs during the first 2 weeks after birth (22). Chrne expression did not change upon treatment with factors known to be associated with neuromuscular junction formation and/or muscle differentiation (CGRP, thyroxine, forskolin, phorbol 12-myristate 13-acetate, A23187, bFGF, or TGFBeta) (22). In the rat, the ε subunit levels increase during the first two weeks of postnatal development from no hybridization signal detected at postnatal day 1 to increasing expression at P5, 9, and 12 (19;23). Expression of the ε subunit is induced locally via a signal restricted to the end-plate region (19). Regulatory elements contribute to the repression of the AChR subunit genes in extrajunctional areas (25). An E box contains a CANNTG consensus target sequence and binds myogenic b-HLH transcription factors of the MyoD gene family (26;27). An 83-nucleotide fragment upstream of the transcription start site of Chrne confers preferential synaptic expression in whole muscle of a LacZ reporter gene (28). In support of this, Sunyer et al. identified a 151 base pair fragment upstream of Chrne start site is required for cell type- and differentiation-specific promoter activity; the activity was independent of the E-box (29). Electrical activity evoked by the motor nerve during development contributes to the transcriptional repression of AChR genes in extrajunctional areas (30-32). During muscle cell determination and differentiation, specific histone modifications are targeted to the Chrne locus (18). During muscle cell determination, K4 dimethylation is induced, while during differentiation trimethylation is induced (18). During determination and differentiation, loss of trimethylation and appearance of monomethylation occurs at K27 (18). K9/14 acetylation are also induced in a developmental pattern (18). Chrne has also been detected in adult mouse diaphragm, mouse airway epithelial cells, and fibroblasts as well as in all brain regions examined (cortex, hippocampus, and cerebellum) (17;33;34). The ɛs splice variant is expressed in skeletal muscle and diaphragm as well as in the cortex, hippocampus, and cerebellum (16;17). The ɛt splice variant was not expressed in skeletal muscle, but was restricted to the brain (17). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Background |
AChR is an ion channel that regulates the flow of water and ions across the cell membrane to mediate synaptic transmission at the neuromuscular junction [Figure 4; (2)]. In the central and peripheral nervous systems, ACh is released from the nerve terminal where it binds to the AChR on the end plate of the muscle fibers to facilitate cation-selective channel opening. Negatively charged amino acids at the ends of the pore prevent negative ions from entering, while encouraging positive ions (e.g., sodium, potassium, and some calcium) to enter. As a result of the large influx of sodium, the membrane depolarizes and signals to the muscle to contract (4;35;36).
The AChR contains five subunits [α2βδγ (fetal-type) or α2βδε (adult-type)] encoded by highly conserved separate genes (29;37;38). Approximately 2 weeks after birth in the mouse, the subunit composition and the characteristics of the AChR changes from low-conductance, long open time to high conductance, brief open time (39). The adult form of the AChR exhibits greater channel conductance to Na+, K+ and Ca2+ than the fetal receptors (40). The shift in AChR composition is due to changes in transcription: Chrne is activated postnatally resulting in expression of the ε subunit, while Chrng (encoding the gamma subunit) expression is down-regulated (22;23;41;42). Each of the AChR subunits interacts with two of its neighboring subunits. AChR assembly occurs in the ER before translocation to the Golgi and the cell surface (3). The AChR has an N-terminal extracellular ligand-binding domain, a membrane-spanning pore, and an intracellular domain [PDB:2BG9; (1)]. The β-barrels from each of the subunits forms the extracellular domain of the AChR and the α-helical M1-M4 domains from each of the subunits forms the transmembrane domain (9). The two binding sites for ACh are at the α-γ (or ε) and α-δ interfaces approximately 40Å from the membrane surface and are on opposite sides of the pore (1). The subunits in the ligand-binding domain are organized around two sets of β-sheets packed into a β-sandwhich and joined through the disulfide bridge forming the Cys loop (1). Each subunit resembles the blade of a propeller when viewed from the synaptic cleft [PDB:1OED; (7)]. The AChR forms a narrow pore through the lipid bilayer and has wider vestibules at both ends. The pore has an inner ring of 5 α-helices (i.e., the M2 domains of the subunits) that curve radially to generate a tapering path for the ions (7). The pore also has an outer ring of 15 α-helices that coil around each other and protect the inner ring from lipids (7). Binding of ACh to the ligand binding domains of the α-subunits causes rotation of the protein chains on opposite sides of the entrance of the pore, widening of the lumen of the pore (7). In the closed state, the inner helix ring come together near the middle of the membrane to form a hydrophobic girdle to prevent ion permeation (43) and are proposed to function as a gate (1;44;45). Additional studies determined that in order for the channel to open, ACh triggers the inner β-sheets of the α-subunits to communicate through to the inner helices that break the gate apart (7;46). Mutations in CHRNE are linked to congenital myasthenic syndrome (associated with acetylcholine receptor deficiency) (OMIM: #608931), autosomal recessive fast-channel myasthenic syndrome (OMIM: #608930), and autosomal dominant slow-channel myasthenic syndrome (OMIM: #601462) (47-51). Myasthenic syndromes are associated with compromised neuromuscular transmission, but the clinical manifestations vary by syndrome subtype [reviewed in (52)]. The slow-channel syndrome can occur at any stage of life (53). Typically, symptoms of the fast-channel syndrome occur in neonates and infants (53-55). Patients with myasthenic syndrome can exhibit hypotonia, delayed motor development, ptosis, ophthalmoplegia, weakness, skeletal deformaties (e.g., arthrogryposis, lordosis, or scoliosis), muscular atrophy, dysphagia, and respiratory difficulty. The myasthenic syndromes occur as the result of abnormal AChR activity after ACh stimulation. In the slow-channel syndrome, the AChR has difficulty closing leading to abnormal entry of calcium into the muscle fiber and subsequent endplate myopathy, while in the fast-channel syndrome, the AChR remains closed [reviewed in (52)]. Mutations in CHRNE often result in the reduced AChR expression and subsequent reduced receptor density on the postsynaptic membrane (53). In addition, there is persistent presence of the fetal form of the AChR that contains the γ subunit (53;55). Patients exhibit some favorable responses to treatment with cholinesterase inhibitors (e.g., pyridostigmine and/or 3,4-diaminopyridine) (56). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Putative Mechanism | Chrne knockout (Chrne-/-) mice appear normal within the first few weeks after birth, but at approximately 1 month of age they become weaker and less active than their littermates (38). In addition, the mice fail to put on weight (by P28 they were at least 40% smaller than wild-type mice) and died between 8 and 14 weeks of age (35;38;47). By 5 weeks of age, muscle atrophy was observed, but the muscle was free from gross pathology; muscle necrosis or apoptosis were not observed (38). The reduced muscle strength is due to a loss in endplate AChR; the mice have approximately 5% of wild-type AChR numbers at the time of death (35). The number of AChRs at the endplates in the Chrne-/- mice are normal until approximately P7 (38). Chrne-/- mice maintain γ-subunit-containing AChRs at their endplates after the usual time of transition (i.e., postnatal day (P) 14) (38). At all ages tested, the endplates from the Chrne-/- mice were of the fetal composition (α2βδγ) (38). The phenotype of the pip-squeak mouse included an inability to gain weight and premature lethality, indicating that there is loss of function of the mutant AChR. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Primers |
PCR Primer pip-squeak_pcr_F: TTGCCTCCAAGTGCCTGACCAAAC pip-squeak_pcr_R: AAATCCGCTGCTGTGTGGATGCTG Sequencing Primer pip-squeak_seq_F: ACCAGATTTATTGTCAGCGGC pip-squeak_seq_R: GTGAACTTTGTGGCTGAGAGC |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genotyping | Pip-squeak genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide transversion. PCR Primers Pip-squeak (F): 5’- TTGCCTCCAAGTGCCTGACCAAAC-3’ Pip-squeak (R): 5’- AAATCCGCTGCTGTGTGGATGCTG-3’ Sequencing Primer Pip-squeak (F): 5’- ACCAGATTTATTGTCAGCGGC-3’ Pip-squeak (R): 5’- GTGAACTTTGTGGCTGAGAGC-3’ PCR program 1) 94°C 2:00 2) 94°C 0:30 3) 55°C 0:30 4) 72°C 1:00 5) repeat steps (2-4) 40X 6) 72°C 10:00 7) 4°C ∞ The following sequence of 483 nucleotides is amplified (Chr.11: 70614796-70615278, GRCm38; NC_000077): ttgcctccaa gtgcctgacc aaaccaccca cccatcttct acttccctga ggagttggac ccacccacat gaccacacaa cccctcctgc aagttcacaa accagattta ttgtcagcgg cctgttttca aaatctcttt cttggggggt gggggagagg tgggtgccag tgcaggctca tggttggatg cacggtgggt aagggagatc aggaacttgg ttgaagtaac ccccaaggaa gatgagagta gaaccaacgc tgaagagcac caaagctgcc caaaaacaga cattgtccag ggccttcccc atacgcaccc agtcggacag ttcctgtgag agagagctta gcgagggagg agcctggagg gcggggcatc tagcactgct ccgcctcaac ctcccaaccc acctctccag tggcttcctg gtctcttgtg ctctcagcca caaagttcac agcatccaca cagcagcgga ttt Primer binding sites are underlined and the sequencing primer is highlighted; the mutated nucleotide (T) is shown in red text (A>T, sense strand; T>A, Chr.+ strand). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References |
44. Unwin, N. (1993) Nicotinic Acetylcholine Receptor at 9 A Resolution. J Mol Biol. 229, 1101-1124.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Science Writers | Anne Murray | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illustrators | Peter Jurek | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Authors | Jeff SoRelle, Zhe Chen, William McAlpine, Noelle Hutchins |